Fluidigm Corporation (FLDM): Price and Financial Metrics
GET POWR RATINGS... FREE!
FLDM Stock Price Chart Interactive Chart >
FLDM Price/Volume Stats
|Current price||$3.71||52-week high||$7.51|
|Prev. close||$3.99||52-week low||$2.67|
|Day high||$4.05||Avg. volume||968,838|
|50-day MA||$3.56||Dividend yield||N/A|
|200-day MA||$4.95||Market Cap||283.76M|
Fluidigm Corporation (FLDM) Company Bio
Fluidigm Corporation develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. The company was founded in 1999 and is based in South San Francisco, California.
Most Popular Stories View All
FLDM Latest News Stream
|Loading, please wait...|
FLDM Latest Social Stream
View Full FLDM Social Stream
Latest FLDM News From Around the Web
Below are the latest news stories about Fluidigm Corp that investors may wish to consider to help them evaluate FLDM as an investment opportunity.
Fluidigm press release (NASDAQ:FLDM): Q4 Non-GAAP EPS of -$0.01 beats by $0.17. Revenue of $38.27M (-14.2% Y/Y) beats by $5.57M....
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the fourth quarter and full year ended December 31, 2021.
Fluidigm Announces Collaboration Agreement with the Abu Dhabi Stem Cells Center to Accelerate Imaging Mass Cytometry in Development of Targeted Stem Cell Therapies
Collaboration Enables Further Expansion of Mass Cytometry in the Middle EastSOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration agreement with the Abu Dhabi Stem Cells Center (ADSCC) for development of targeted stem cell therapies and research applications utilizing two Fluidigm® mass cytometry and tissue im
Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement for a special meeting of stockholders (the “Special Meeting”) at which Fluidigm stockholders will have the opportunity to consider and vote upon various items related to the proposed and previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (“Casdi
Worldwide Spatial OMICS Industry to 2028 - Featuring 10x Genomics, NanoString Technologies and PerkinElmer Among Others - ResearchAndMarkets.com
The "Global Spatial OMICS Market, By Sample Type, By End Use, By Technology, By Product, By Workflow, Estimation & Forecast, 2018 - 2028" report has been added to ResearchAndMarkets.com''s offering. The global spatial OMICS market held a market value of USD 230.2 million in 2020 and is estimated to reach USD 506.6 million by the year 2028. The market is anticipated to register a CAGR of 10.3% during the forecast period. Companies Mentioned 10x Genomics S2 Genomics, Inc. NanoString Technologies Seven Bridges Genomics PerkinElmer, Inc. Bio-Techne Danaher Corporation IonPath, Inc. Millennium Science Pty Ltd Akoya Biosciences, Inc. Fluidigm Corporation Diagenode Diagnostics Biognosys AG Rebus Biosystems Ultivue, Inc. BioSpyder Technologies Bruker Spatial omics combines the molecular scrutin...
FLDM Price Returns